NASDAQ:PSTV Plus Therapeutics (PSTV) Stock Price, News & Analysis → The 'Smart Money' Is Ready for May 1st Are You? (From Stansberry Research) (Ad) Free PSTV Stock Alerts $1.60 -0.03 (-1.84%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$1.55▼$1.6450-Day Range$1.60▼$2.1852-Week Range$0.97▼$5.09Volume8,444 shsAverage Volume31,464 shsMarket Capitalization$6.85 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial Media Get Plus Therapeutics alerts: Email Address Plus Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside525.0% Upside$10.00 Price TargetShort InterestHealthy1.11% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.41Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.99) to ($1.03) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.18 out of 5 stars 3.5 Analyst's Opinion Consensus RatingPlus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoveragePlus Therapeutics has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.11% of the float of Plus Therapeutics has been sold short.Short Interest Ratio / Days to CoverPlus Therapeutics has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Plus Therapeutics has recently increased by 45.34%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPlus Therapeutics does not currently pay a dividend.Dividend GrowthPlus Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PSTV. Previous Next 1.9 News and Social Media Coverage News SentimentPlus Therapeutics has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Plus Therapeutics this week, compared to 1 article on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Plus Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.32% of the stock of Plus Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 3.28% of the stock of Plus Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Plus Therapeutics are expected to decrease in the coming year, from ($0.99) to ($1.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Plus Therapeutics is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Plus Therapeutics is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPressThe system that called 2023’s top 7 stocks is at it again…Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.Just follow this link here! About Plus Therapeutics Stock (NASDAQ:PSTV)Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead drug candidate is Rhenium-186Re obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.Read More PSTV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PSTV Stock News HeadlinesApril 23, 2024 | americanbankingnews.comPlus Therapeutics (NASDAQ:PSTV) Trading Up 1.8%April 22, 2024 | finance.yahoo.comMicro-Cap Brain Cancer Focused Plus Therapeutics Poised To Receive $3M From US Department of DefenseApril 25, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… April 22, 2024 | globenewswire.comPlus Therapeutics Receives $3 Million Award Recommendation from the United States Department of DefenseApril 19, 2024 | finance.yahoo.comPlus Therapeutics, Inc. (PSTV)April 9, 2024 | finance.yahoo.comNeuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus’ Management TeamApril 9, 2024 | globenewswire.comNeuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D.March 27, 2024 | finance.yahoo.comPlus Therapeutics to Present at the National Comprehensive Cancer Network Annual ConferenceApril 25, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… March 25, 2024 | finance.yahoo.comPlus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell DiagnosticMarch 23, 2024 | markets.businessinsider.comBuy Rating Affirmed for Plus Therapeutics Amidst Clinical Advancements and Industry TailwindsMarch 11, 2024 | finance.yahoo.comPlus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal MetastasesMarch 7, 2024 | finance.yahoo.comPlus Therapeutics Full Year 2023 Earnings: Beats ExpectationsMarch 7, 2024 | finance.yahoo.comPlus Therapeutics, Inc. (NASDAQ:PSTV) Q4 2023 Earnings Call TranscriptMarch 6, 2024 | finance.yahoo.comQ4 2023 Plus Therapeutics Inc Earnings CallMarch 5, 2024 | investorplace.comPSTV Stock Earnings: Plus Therapeutics Beats EPS, Beats Revenue for Q4 2023March 5, 2024 | globenewswire.comPlus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business HighlightsFebruary 29, 2024 | msn.comIMUNON stock rallies 19% on early results for COVID-19 vaccineFebruary 27, 2024 | finance.yahoo.comPlus Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on March 5, 2024February 21, 2024 | morningstar.comPlus Therapeutics Inc PSTVDecember 18, 2023 | finanznachrichten.dePlus Therapeutics Inc.: Plus Updates Financial and Cash Guidance for 2024December 18, 2023 | finance.yahoo.comPlus Updates Financial and Cash Guidance for 2024December 12, 2023 | finance.yahoo.comPlus Therapeutics Partners With K2bio for Development of Novel Tests for Cerebrospinal Fluid (CSF) Tumor Cell and Molecular Biomarker AnalysesNovember 29, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Halozyme (HALO), HUTCHMED (HCM) and Plus Therapeutics (PSTV)November 20, 2023 | msn.comFortress Biotech, Plus Therapeutics among healthcare moversNovember 20, 2023 | finance.yahoo.comPlus Therapeutics Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader WebinarNovember 15, 2023 | finance.yahoo.comPlus Therapeutics to Host Virtual KOL Event on New Phase 2 ReSPECT-GBM Data in Recurrent Glioblastoma Presented at the Society for NeuroOncology (SNO) Conference on Monday, November 20, 2023See More Headlines Receive PSTV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Plus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/05/2024Today4/25/2024Next Earnings (Estimated)4/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:PSTV CUSIPN/A CIK1095981 Webwww.plustherapeutics.com Phone737-255-7194Fax858-450-4335Employees20Year Founded1996Price Target and Rating Average Stock Price Target$10.00 High Stock Price Target$12.00 Low Stock Price Target$8.00 Potential Upside/Downside+525.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($33.7590) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,320,000.00 Net Margins-271.04% Pretax Margin-271.04% Return on Equity-805.57% Return on Assets-97.73% Debt Debt-to-Equity RatioN/A Current Ratio0.92 Quick Ratio0.92 Sales & Book Value Annual Sales$4.91 million Price / Sales1.39 Cash FlowN/A Price / Cash FlowN/A Book Value($0.30) per share Price / Book-5.33Miscellaneous Outstanding Shares4,280,000Free Float4,177,000Market Cap$6.85 million OptionableNot Optionable Beta0.59 Social Links 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Marc H. Hedrick M.B.A. (Age 61)M.D., President, CEO & Director Comp: $945.34kMr. Andrew J. Sims CPA (Age 51)VP of Finance & CFO Comp: $498.51kDr. Norman D. LaFrance FACNP (Age 76)FACP, M.D., Chief Medical Officer & Senior VP Comp: $646.02kMs. Desiree Smith (Age 60)Corporate Controller, Principal Financial & Accounting Officer Dr. John K. Fraser (Age 63)Chief Scientist Key CompetitorsVivos TherapeuticsNASDAQ:VVOSVapothermNYSE:VAPOIntelligent Bio SolutionsNASDAQ:INBSAvingerNASDAQ:AVGRVenus ConceptNASDAQ:VEROView All CompetitorsInsidersMarc H HedrickSold 2,068 sharesTotal: $4,053.28 ($1.96/share)Robert P LenkBought 1,000 shares on 11/15/2023Total: $1,770.00 ($1.77/share)Robert P LenkBought 4,000 shares on 11/13/2023Total: $5,720.00 ($1.43/share)Robert P LenkBought 2,000 shares on 11/10/2023Total: $2,900.00 ($1.45/share)Robert P LenkBought 5,000 shares on 11/8/2023Total: $8,250.00 ($1.65/share)View All Insider Transactions PSTV Stock Analysis - Frequently Asked Questions Should I buy or sell Plus Therapeutics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Plus Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PSTV shares. View PSTV analyst ratings or view top-rated stocks. What is Plus Therapeutics' stock price target for 2024? 1 analysts have issued 1 year target prices for Plus Therapeutics' shares. Their PSTV share price targets range from $8.00 to $12.00. On average, they predict the company's stock price to reach $10.00 in the next year. This suggests a possible upside of 525.0% from the stock's current price. View analysts price targets for PSTV or view top-rated stocks among Wall Street analysts. How have PSTV shares performed in 2024? Plus Therapeutics' stock was trading at $1.7501 at the beginning of the year. Since then, PSTV stock has decreased by 8.6% and is now trading at $1.60. View the best growth stocks for 2024 here. Are investors shorting Plus Therapeutics? Plus Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 46,800 shares, an increase of 45.3% from the March 15th total of 32,200 shares. Based on an average daily trading volume, of 31,400 shares, the days-to-cover ratio is currently 1.5 days. Approximately 1.1% of the shares of the company are short sold. View Plus Therapeutics' Short Interest. When is Plus Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024. View our PSTV earnings forecast. How were Plus Therapeutics' earnings last quarter? Plus Therapeutics, Inc. (NASDAQ:PSTV) released its quarterly earnings results on Tuesday, March, 5th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.78) by $0.08. The company earned $1.31 million during the quarter, compared to the consensus estimate of $1.26 million. Plus Therapeutics had a negative net margin of 271.04% and a negative trailing twelve-month return on equity of 805.57%. When did Plus Therapeutics' stock split? Plus Therapeutics shares reverse split on the morning of Monday, May 1st 2023. The 1-15 reverse split was announced on Monday, May 1st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Plus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Plus Therapeutics investors own include Advanced Micro Devices (AMD), Trevena (TRVN), Chimerix (CMRX), Genocea Biosciences (GNCA), Sorrento Therapeutics (SRNE), Akero Therapeutics (AKRO), Aldeyra Therapeutics (ALDX), Aileron Therapeutics (ALRN) and CymaBay Therapeutics (CBAY). How do I buy shares of Plus Therapeutics? Shares of PSTV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PSTV) was last updated on 4/25/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryNew Trump BombshellThe Freeport Society1970’s computer coder issues shocking A.I. warningTradeSmithNew York goes dark, then America.Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Plus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
